Book contents
- CASE STUDIES Stahl’s Essential Psychopharmacology
- Reviews
- CASE STUDIES: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- List of icons
- Abbreviations
- Case 1: The salutatorian who couldn’t speak: selective serotonin reuptake inhibitor (SSRI)-refractory anxiety in an adolescent
- Case 2: From anxious to activated: selective serotonin reuptake inhibitor (SSRI)-related activation
- Case 3: The girl who couldn’t sleep: posttraumatic stress disorder (PTSD) in a young girl
- Case 4: Depressed and still depressed: major depressive disorder (MDD) in an adolescent
- Case 5: A 13-year-old adolescent who feels “amazing”: selective serotonin reuptake inhibitor (SSRI)-induced mania in an adolescent
- Case 6: Counting on a cure: obsessive compulsive disorder (OCD) in an adolescent
- Case 7: Struggles in the second grade: attention-deficit hyperactivity disorder (ADHD) in a child
- Case 8: From prodrome to psychosis: early-onset schizophrenia
- Case 9: Too much, too little, or just right? Lithium dosing in an adolescent
- Case 10: Tic, tic, tic: motor and vocal tics in a boy
- Case 11: How slow can you go? Selective serotonin reuptake inhibitor (SSRI) withdrawal and discontinuation in an adolescent
- Case 12: The adolescent who doesn’t eat: anorexia nervosa in an adolescent
- Case 13: High or higher antidepressant concentrations? Cannabis-related drug interactions in an adolescent
- Case 14: The boy whose bed was always wet: nocturnal enuresis in a child
- Case 15: Counting sheep and counting treatment trials: insomnia disorder in an adolescent
- Case 16: Second-generation antipsychotics/mixed dopamine–serotonin receptor agonists (SGAs), side effects, and the autism spectrum: SGA-related side effects in a boy with autism spectrum disorder (ASD)
- Case 17: The “standard treatment” is earning a “D”: treatment-resistant schizophrenia
- Case 18: Symptoms, side effects, or both? Selective serotonin reuptake inhibitor (SSRI) tolerability and physical symptoms in an anxious adolescent
- Book part
- Case Studies Index
- Drugs Index
- References
Case 6: Counting on a cure: obsessive compulsive disorder (OCD) in an adolescent
Published online by Cambridge University Press: 09 February 2024
Book contents
- CASE STUDIES Stahl’s Essential Psychopharmacology
- Reviews
- CASE STUDIES: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- List of icons
- Abbreviations
- Case 1: The salutatorian who couldn’t speak: selective serotonin reuptake inhibitor (SSRI)-refractory anxiety in an adolescent
- Case 2: From anxious to activated: selective serotonin reuptake inhibitor (SSRI)-related activation
- Case 3: The girl who couldn’t sleep: posttraumatic stress disorder (PTSD) in a young girl
- Case 4: Depressed and still depressed: major depressive disorder (MDD) in an adolescent
- Case 5: A 13-year-old adolescent who feels “amazing”: selective serotonin reuptake inhibitor (SSRI)-induced mania in an adolescent
- Case 6: Counting on a cure: obsessive compulsive disorder (OCD) in an adolescent
- Case 7: Struggles in the second grade: attention-deficit hyperactivity disorder (ADHD) in a child
- Case 8: From prodrome to psychosis: early-onset schizophrenia
- Case 9: Too much, too little, or just right? Lithium dosing in an adolescent
- Case 10: Tic, tic, tic: motor and vocal tics in a boy
- Case 11: How slow can you go? Selective serotonin reuptake inhibitor (SSRI) withdrawal and discontinuation in an adolescent
- Case 12: The adolescent who doesn’t eat: anorexia nervosa in an adolescent
- Case 13: High or higher antidepressant concentrations? Cannabis-related drug interactions in an adolescent
- Case 14: The boy whose bed was always wet: nocturnal enuresis in a child
- Case 15: Counting sheep and counting treatment trials: insomnia disorder in an adolescent
- Case 16: Second-generation antipsychotics/mixed dopamine–serotonin receptor agonists (SGAs), side effects, and the autism spectrum: SGA-related side effects in a boy with autism spectrum disorder (ASD)
- Case 17: The “standard treatment” is earning a “D”: treatment-resistant schizophrenia
- Case 18: Symptoms, side effects, or both? Selective serotonin reuptake inhibitor (SSRI) tolerability and physical symptoms in an anxious adolescent
- Book part
- Case Studies Index
- Drugs Index
- References
Summary
Which of the following represents the best and most evidence-based intervention for an adolescent with OCD who has failed three SSRIs and cognitive behavior therapy (CBT)?
- Type
- Chapter
- Information
- Case Studies: Stahl's Essential PsychopharmacologyChildren and Adolescents, pp. 77 - 94Publisher: Cambridge University PressPrint publication year: 2023
References
Bloch, M. H., Storch, E. A. Assessment and management of treatment-refractory obsessive-compulsive disorder in children. J Am Acad Child Adolesc Psychiatry 2015; 54: 251–62. https://doi.org/10.1016/j.jaac.2015.01.011Google Scholar
Furness, S., Worthington, H. V., Bryan, G., Birchenough, S., McMillan, R. Interventions for the management of dry mouth: topical therapies. Cochrane Database Syst Rev 2011; 12: CD008934. https://doi.org/10.1002/14651858.CD008934.pub2Google Scholar
Geller, D. A., Hoog, S. L., Heiligenstein, J. H., et al. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry 2001; 40: 773–9. https://doi.org/10.1097/00004583-200107000-00011Google Scholar
Geller, D. A., Biederman, J., Stewart, S. E., et al. Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatry 2003; 160: 1919–28. https://doi.org/10.1176/appi.ajp.160.11.1919Google Scholar
Hunter, K. D., Wilson, W. S. The effects of antidepressant drugs on salivary flow and content of sodium and potassium ions in human parotid saliva. Arch Oral Biol 1995; 40: 983–9. https://doi.org/10.1016/0003-9969(95)00079-5Google Scholar
Luft, M. J., Aldrich, S.L., Poweleit, E., et al. Thyroid function screening in children and adolescents with mood and anxiety disorders. J Clin Psychiatry 2019; 80: 18m12626. https://doi.org/10.4088/JCP.18m12626Google Scholar
Mavissakalian, M. R., Jones, B., Olson, S., Perel, J. M. Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels. J Clin Psychopharmacol 1990; 10: 261–8. PMID: 2286699.Google Scholar
Pediatric OCD Treatment Study (POTS) Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA 2004; 292: 1969–76. https://doi.org/10.1001/jama.292.16.1969Google Scholar
Peris, T. S., Sugar, C. A., Lindsey Bergman, R., et al. Family factors predict treatment outcome for pediatric obsessive compulsive disorder. J Consult Clin Psychol 2012; 80: 255–63. https://doi.org/10.1037/a0027084Google Scholar
Scahill, L., Riddle, M. A., McSwiggin-Hardin, M., et al. Children’s Yale-Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry 1997; 36: 844–52. https://doi.org/10.1097/00004583-199706000-00023Google Scholar
Stahl, S., Grady, M. M., Muntner, N. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 5th edn. Cambridge, UK: Cambridge University Press, 2021.Google Scholar
Stein, D. J., Costa, D. L. C., Lochner, C., et al. Obsessive-compulsive disorder. Nat Rev Dis Primers 2019; 5: 52. https://doi.org/10.1038/s41572-019-0102-3Google Scholar
Storch, E. A., Bussing, R., Small, B. J., et al. Randomized, placebo-controlled trial of cognitive-behavioral therapy alone or combined with sertraline in the treatment of pediatric obsessive-compulsive disorder. Behav Res Ther 2013; 51: 823–9. https://doi.org/10.1016/j.brat.2013.09.007Google Scholar
Storch, E. A., Peris, T. S., de Nadai, A., et al. Little doubt that CBT works for pediatric OCD. J Am Acad Child Adolesc Psychiatry 2020; 59: 785–7. https://doi.org/10.1016/j.jaac.2020.01.026Google Scholar
Varigonda, A. L., Jakubovski, E., Bloch, M. H. Systematic review and meta-analysis: early treatment responses of selective serotonin reuptake inhibitors and clomipramine in pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2016; 55: 851–9.e2. https://doi.org/10.1016/j.jaac.2016.07.768Google Scholar